

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CANbridge Pharmaceuticals Inc.**

**北海康成製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1228)**

## **NOTICE OF DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, August 24, 2022 for the purpose of, among other matters, considering and approving the unaudited interim results of the Company and its subsidiaries for the six months ended June 30, 2022 and its publication and considering the payment of an interim dividend (if any).

By order of the Board  
**CANbridge Pharmaceuticals Inc.**  
**Dr. James Qun Xue**  
*Chairman*

Hong Kong, August 11, 2022

*As at the date of this announcement, the board of directors of the Company comprises Dr. James Qun Xue as executive director; Dr. Kan Chen, Dr. Derek Paul Di Rocco and Mr. Edward Hu as non-executive directors; and Mr. James Arthur Geraghty, Dr. Richard James Gregory, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive directors.*